. | Viscera . | . | . | . | Brain . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genotype . | n . | Situs solitus (%) . | Situs inversus (%) . | Heterotaxia (%) . | n . | Correct (%) . | Reversed (%) . | |||||
Wild type | 100 | 97.0 | 0.0 | 3.0 | 74 | 97 | 3 | |||||
cuptc321 | 97 | 35.0 | 33.0 | 32.0 | 41 | 41 | 59 | |||||
cupty30b | 98 | 37.8 | 45.9 | 16.3 | 85 | 45 | 55 | |||||
augMO (2ng) | 54 | 53.7 | 35.2 | 11.1 | - | - | - | |||||
SpMO (9ng) | 23 | 39.1 | 26.1 | 34.8 | - | - | - |
. | Viscera . | . | . | . | Brain . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genotype . | n . | Situs solitus (%) . | Situs inversus (%) . | Heterotaxia (%) . | n . | Correct (%) . | Reversed (%) . | |||||
Wild type | 100 | 97.0 | 0.0 | 3.0 | 74 | 97 | 3 | |||||
cuptc321 | 97 | 35.0 | 33.0 | 32.0 | 41 | 41 | 59 | |||||
cupty30b | 98 | 37.8 | 45.9 | 16.3 | 85 | 45 | 55 | |||||
augMO (2ng) | 54 | 53.7 | 35.2 | 11.1 | - | - | - | |||||
SpMO (9ng) | 23 | 39.1 | 26.1 | 34.8 | - | - | - |
Viscera and brain data were collected at 48 hpf and 72 hpf, respectively. MOs were injected between the one- and four-cell stage. The laterality defects associated with 2 ng of pkd2 augMO are less severe than those in embryos injected with a higher dosage, but more general patterning defects can be seen at higher MO concentrations.